Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 11, 2007, Pages 5152-5159

  Kusari, Jyotirmoy ^a   Zhou, Sheila ^a   Padillo, Edwin ^a   Clarke, Kenneth G ^a   Gil, Daniel W ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MEMANTINE; STREPTOZOCIN; VASCULOTROPIN; AMINO ACID RECEPTOR BLOCKING AGENT; COLORING AGENT; EVANS BLUE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RETINA BARRIER; BODY WEIGHT; BROWN NORWAY RAT; CELL COUNT; CHEMOPROPHYLAXIS; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFECT; ELECTRORETINOGRAPHY; GLUCOSE BLOOD LEVEL; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; RETINA BLOOD VESSEL; RETINA GANGLION CELL; RETINA NERVE CELL; STREPTOZOCIN DIABETES; UPREGULATION; VITREOUS BODY; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; OPTIC NERVE DISEASE; PATHOLOGY; RETINA;

ANIMALS; BLOOD GLUCOSE; BLOOD-RETINAL BARRIER; BODY WEIGHT; CELL COUNT; COLORING AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; EVANS BLUE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMANTINE; OPTIC NERVE DISEASES; RATS; RATS, INBRED BN; RETINA; RETINAL GANGLION CELLS; RETINAL VESSELS; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 38449119665     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0427     Document Type: Article

References (64)

1. Leal EC, Santiago AR, Ambrosio AF. Old and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. Curr Drug Targets CNS Neurol Disord. 2005;4:421-434.
2. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27:283-290.
3. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev. 1995;11:109-120.
4. Ishibashi T, Inomato H. Ultrastructure of retinal vessels in diabetic patients. Br J Ophthalmol. 1993;77:574-578.
5. Wallow IHL, Engerman RL. Permeability and patency of retinal blood vessels in experimental diabetes. Invest Ophthalmol Vis Sci. 1977;16:447-461.
6. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52:864-871.
7. Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications. 2003;17:374-379.
8. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003;458:283-289.
9. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest. 1998;102:783-791.
10. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes. 2003;52: 506-511.
11. Chihara E, Matsuoka T, Ogura Y, Matsumura M. retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. Ophthalmology. 1993;100:1147-1151.
12. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res. 2002;74:615-625.
13. Planells-Cases R, Lerma J, Ferrer-Montiel A. Pharmacological intervention at ionotropic glutamate receptor complexes. Curr Pharm Des. 2006;12:3583-3596.
14. Kowluru RA, Engerman, RL, Case GL, Kern TS. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int. 2001;38:385-390.
15. Ambati J, Chalam KV, Chawla DK, et al. Elevated γ-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115:1161-1166.
16. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes. 1998;47:815-820.
17. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci. 2002;43:3109-3116.
18. Ng YK, Zeng XX, Ling EA. Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Res. 2004;1018:66-72.
19. Smith SB. Diabetic retinopathy and the NMDA receptor. Drug News Perspect. 2002;15:226-232.
20. Xu X, Zhu Qi, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res. 2004;28:251-256.
21. Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retinal Eye Res. 2003;22:1-29.
22. Funatsu H, Yamashita H. Pathophysiology of diabetic retinopathy. Drug News Perspect. 2002;15:633-639.
23. Hammes H-P, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes. 1998;47:401-406.
24. Funatsu H, Yamashita H, Nakanishi H, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2002;86: 311-315.
25. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133:537-543.
26. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-77.
27. Lutty GA, McLoad DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroids. Arch Ophthalmol. 1996;114:971-977.
28. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells: Penn State Retina Research Group. Diabetes. 1998;47:1953-1959.
29. Block F, Schwartz M. Memantine reduces functional and morphological consequences induced by global ischemia in rats. Neurosci Lett. 1996;208:41-44.
30. WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma. 2002;11:474-480.
31. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest Ophthalmol Vis Sci. 2004;45:2640-2651.
32. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm. 1992;4:277-282.
33. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebo-controlled study. Arzeimittelforschung. 1992;42:904-913.
34. Gauthier S, Herrmann N, Ferreri F, Aqbokou C. Use of memantine to treat Alzheimer's disease. CMAJ. 2006;175:501-502.
35. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42: 2849-2855.
36. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413.
37. Do carmo A, Ramos P, Reis A, Proenca R, Cunha-vaz JG. Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res. 1998;67:569-575.
38. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood retinal barrier breakdown in human diabetes. Am J Pathol. 1989;134:231-235.
39. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998-1003.
40. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50: 1774-1778.
41. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
42. Obrosova IG, Minchenko AG, Marinescu V, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia. 2001;44: 1102-1110.
43. Lei B, Perlman I. The contribution of voltage- and time-dependent potassium conductances to the electroretinogram in rabbits. Vis Neurosci. 1999;16:743-754.
44. Karwoski CJ, Xu X. Current source-density analysis of light-evoked field potentials in rabbit retina. Vis Neurosci. 1999;16:369-377.
45. Ripps H, Witkovsky P. Neuron-glia interaction in the brain and retina. In: Osborne NN, Chader GJ. Progress in Retinal Research. Oxford: Pergamon Press; 1985:181-219.
46. Cruz RD, Adachi-Usami E. Quantitative evaluation of electroretinogram before cataract surgery. Jpn J Ophthalmol. 1989,33:451-457.
47. Galloway N. Electrophysiological testing of eyes with opaque media. Eye. 1988;2:615-624.
48. Park S-H, Park J-W, Park S-J, et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia. 2003;46:1260-1268.
49. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci. 2004;45:3330-3336.
50. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007;56:337-345.
51. Okouchi M, Okayama N, Kimura R, et al. Insulin protection against carbonyl and hyperglycemic stress-induced neuronal cell apoptosis. Diabetes. 2007;56(suppl 1):A345.
52. Lipton S, Rosenberg P. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-662.
53. 2-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296:216-223.
54. Brooks DE, Garcia GA, Dreyer EB, Zurakowski D, Franco-Bourland RE. Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res. 1997;58:864-867.
55. 3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices. Eur J Pharmacol. 1992; 224:51-56.
56. Bencherif M, Hauser TA, Jordan KG, Gatto GJ. Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors. J Mol Neurosci. 2006;30:17-18.
57. 5B receptor subunits in mammalian retinae: potential pre-synaptic modulators of photoreceptors. Brain Res. 2001;896:77-85.
58. Dmitrieva NA, Strang CE, Keyser KT. Expression of alpha 7 nicotinic acetylcholine receptors by bipolar, amacrine, and ganglion cells of the rabbit retina. J Histochem Cytochem. 2007;55:461-476.
59. Rammes G, Rupprecht R, Ferrari, U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonize 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a noncompetitive manner. Neurosci Lett. 2001;306:81-84.
60. Maskell PD, Speder P, Newberry NR, Bermudez I. Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br J Pharmacol. 2003; 140:1313-1319.
61. Poulaki V, Qin W, Joussen AM, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF. J Clin Invest. 2002;109: 805-815.
62. Mahmmoud YA. Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. Br J Pharmacol. 2007;150:200-208.
63. Saluja I, O'Regan MH, Song D, Phillis JW. Activation of cPLA2, PKC, ERKs in the rat cerebral cortex during ischemia/reperfusion. Neurochem Res. 1999;24:669-677.
64. Kaur C, Sivakumar V, Foulds WS. Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci. 2006;47:1126-1141.